Yubico More than Doubles Global Reach of YubiKeys for Enterprises to 175 Countries and 24 Territories, Simplifying Passwordless at Scale
Yubico (NASDAQ STOCKHOLM: YUBICO), the leading provider of hardware authentication security keys, today announced the expanded availability of YubiKey as a Service to all countries in the European Union (EU). This allows organizations to be more agile and flexible in their adoption of phishing-resistant YubiKeys, and builds upon the company's existing reach in markets such as the United States, Canada, Japan, Singapore, Australia, India and the UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520271350/en/
Additionally, the company announced the expanded availability of YubiEnterprise Delivery across 117 new locations around the world. Now totalling 199 locations (175 countries and 24 territories), this more than doubles existing delivery coverage of YubiKeys to both office and remote users in a fast and turnkey way.
“Enterprises today are facing evolving cyber threats like Artificial Intelligence (AI)-driven phishing attacks,” said Jeff Wallace, senior vice president of product at Yubico. “By expanding our global reach of YubiKey as a Service and YubiEnterprise Delivery to 175 countries, we’re accelerating our ability to deliver and deploy device-bound passkey solutions that address the biggest threat facing businesses today from stolen login credentials. This expansion enables us to meet growing demand and accelerates adoption – enabling faster, more affordable delivery of pre-configured YubiKeys to markets like the EU and APJ, where regulatory pressures for phishing-resistant authentication are intensifying.”
Seamless user onboarding of YubiKeys with YubiKey as a Service
Rolling out phishing-resistant, passwordless security just got easier for all EU countries through the expansion of YubiKey as a Service. This innovative service provides enterprises with flexibility and simplifies the acquisition and fast roll out of phishing-resistant multi-factor authentication (MFA) with impactful cost savings. The Yubico Enrollment Suite, available exclusively through this service, now enables enterprises in these markets to accelerate passwordless adoption and seamless user onboarding with pre-configured keys to their users. This includes Yubico FIDO Pre-reg for factory-programmed, pre-registered keys as well as YubiEnroll client for in-person onboarding via Okta and Microsoft Entra ID – with more identity providers (IdPs) to follow.
Through these offerings, Yubico is aligning security with operational efficiency– helping organizations future-proof their workforce against evolving phishing threats.
Turnkey global delivery: YubiEnterprise Delivery
Getting hardware security keys into users’ hands – anywhere – is critical and needs to be fast and easy. As part of YubiKey as a Service, YubiEnterprise Delivery helps organizations achieve this by providing IT teams with powerful capabilities to easily manage the delivery of hardware security keys to users, while accelerating the adoption of strong authentication.
Additionally, organizations gain critical visibility into available inventory and consumption patterns of YubiKeys to ensure identification of any gaps in protection against phishing attacks. YubiEnterprise Delivery will continue to make it easy and flexible for enterprises to adopt phishing-resistant MFA and passwordless that stops account takeovers and credential phishing threats.
For more information on YubiKey as a Service and YubiEnterprise Delivery, visit yubico.com or contact our team today. For customers with a need to ship to more countries not currently on the supported list, reach out to your local Yubico representative here.
About Yubico
Yubico (NASDAQ STOCKHOLM: YUBICO), the inventor of the YubiKey, offers the gold standard for phishing-resistant multi-factor authentication (MFA), stopping account takeovers in their tracks and making secure login easy and available for everyone.
Since the company was founded in 2007, it has been a leader in setting global standards for secure access to computers, mobile devices, servers, browsers, and internet accounts. Yubico is a creator and core contributor to the FIDO2, WebAuthn, and FIDO Universal 2nd Factor (U2F) open authentication standards, and is a pioneer in delivering modern, hardware-based passkey authentication security at scale to customers in over 160 countries.
Yubico’s solutions enable passwordless logins using the most secure form of passkey technology. YubiKeys work out-of-the-box across hundreds of consumer and enterprise applications and services, delivering strong security with a fast and easy experience.
As part of its mission to make the internet more secure for everyone, Yubico donates YubiKeys to organizations helping at-risk individuals through the philanthropic initiative, Secure it Forward. The company is headquartered in Stockholm and Santa Clara, CA. For more information on Yubico, visit us at www.yubico.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520271350/en/
Contacts
Media Contacts:
Yubico Media Relations
Press@yubico.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom